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The use of complementary and alternative medicine methods such as acupuncture in
palliative care has increased over the past years. Well-planned trials are warranted to
show its effectiveness in relieving distressing symptoms. The development of treatment
schemes to be used in the trial for both acupuncture and medical symptom control is
challenging, as both acupuncture and palliative care are highly individualized. Thus, stan-
dardized care plans of a randomized controlled trial will have difficulties in producing
treatment results that compare to the clinical practice. As an alternative, treatment pro-
tocols for both acupuncture and medical symptom control of dyspnea, pruritus, hypersal-
ivation, depression, anxiety, and xerostomia were designed with the input of experts.
They are designed to provide sufficient symptom control and comparability for a three-
arm, randomized controlled trial. Medical symptom control will be provided to all groups.
The two control groups will be medical treatment and sham-laser acupuncture.oliklinik fu¨r Orthopa¨die, Physikalische Medizin und Rehabilitation, Klinikum der Universita¨t Mu¨nchen,
Germany.
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Palliative care aims at the improvement of the quality of life
for patients with progressive incurable diseases [1]. Ac-
cording to the World Health Organization, the control of
distressing symptoms within these patients is a high priority
[2]. Usually, this goal is achieved by a highly individualized
care plan combining medical, social, and spiritual care.
Complementary and alternative medicine (CAM) plays an
increasing role in the treatment of these patients [3,4].
Acupuncture is one of themost popular CAMmethods [5]. It is
a relatively safe procedure, assuming that rules are followed
[6]. During recent years, an extensive amount of research
regarding the effectiveness of acupuncture in treatment of
cancer symptoms has been performed [7]. To date, there is
some evidence for the treatment of chemotherapy-induced
nausea and vomiting [8,9], pain [10], hot flashes [11,12],
insomnia [13], myelosuppression [14,15], and fatigue [16] by
acupuncture. For other important symptoms like e.g. dys-
pnea, depression and anxiety, there is still a lack of enough
high-quality research to gather scientific evidence. To keep
track of the principles of evidence-based medicine, more
well-planned trials are necessary.
The design of clinical trials has been an important topic
in acupuncture research for some years now [17e19].
Quality criteria have been published [20,21], and there is
an ongoing discussion regarding the choice of the control
(sham) treatment [22,23]. Therefore, any acupuncture trial
has to consider the design of treatment schemes as well as
the control device.
The choice of the control treatment in palliative care is
equally challenging: In the daily palliative practice, an
effective treatment often consists of a combination of the
various different available medications. In the context of a
randomized controlled trial, an individualized pharmaco-
logical combination is difficult to combine with the
required comparability. Considering the variety and
different intensity of the symptoms, a practitioner experi-
enced in palliative care is usually required for optimum
symptom control [24]. Therefore, we decided to involve
several experts in the field of palliative care into the
configuration of the pharmacological control for this trial.
Taking all these objectives into consideration, for the
design of this trial evaluating the effectiveness of
acupuncture for symptom control of highly relevant and
distressing symptoms such as dyspnea, itching, hypersali-
vation, depression, anxiety, and xerostomia in palliative
care (the AcuPall Study), it was required to develop:
1. Acupuncture treatment schemes with semistandardized
choice of acupuncture points.
2. Pharmacological treatment schemes for an optimum of
symptom control in every group.
2. Materials and methods
2.1. Design
The AcuPall study is a three-arm, partially blinded, ran-
domized controlled trial. It investigates the efficacy of (a)
pharmacological symptom control without additionaltreatment versus (b) add-on acupuncture versus (c) add-on
sham laser acupuncture in a palliative care setting. The six
different investigated symptoms are dyspnea, pruritus, hy-
persalivation, xerostomia, depression, and anxiety. Phar-
macological treatment follows specially designed protocols.
Treatment will be provided to all patients, ensuring that a
sufficient symptom control is guaranteed. First, there will be
the pilot study as an exploratory part of the trial. It aims to
recruit 60 patients per symptom. A sample size calculation
will be performed for the confirmatory part of the trial, ac-
cording to the size of observed effects. Apart from the
sample size calculation, the design will be similar in both
parts: After randomization, patients in both acupuncture
groups receive three treatment sessions per week over a
minimum period of 2 weeks (maximum 4 weeks). Psycho-
logical, social, and spiritual care will be provided to all pa-
tients. The total follow-up study period per patient is
6 weeks. The study protocol is in accordance to the decla-
ration of Helsinki and the “ICH E6 Guideline for Good Clinical
Practice.” Written informed consent is obtained from all
patients. Ethical approval has been given by the Ethics
Committee of the University of Munich, Munich, Germany
(number 146-09).
2.2. Randomization and blinding
For each symptom separately, patients will be randomized,
using a series of sealed, sequentially numbered envelopes
containing the treatment assignments. The envelopeswill be
prepared by an external person. When a patient fulfils the
inclusion criteria, the acupuncturist will open the lowest
numbered envelope to reveal the patient’s group allocation.
Neither the physician prescribing pharmacological treat-
ment according to the treatment protocols nor the patient
will know if they receive sham or verum treatment. Patients
will be told that they will receive acupuncture, laser
acupuncture, or standard medical treatment. They are
further told that one treatment of the two types of
acupuncture will be a placebo treatment. It will be left open
if needle or laser acupuncture will be the sham treatment.
2.3. Patients
Patients will be recruited from the ward of the Interdisci-
plinary Palliative Care Centre, University of Munich and
three other palliative care wards at community hospitals in
Munich connected to the university and at the university
hospital of the Paracelsus Medical University in Salzburg.
Exclusion criteria are as follows: patients younger than
18 years, severe impairment of blood coagulation,
noncompliance, pregnancy or lactation, acupuncture or
transdermal electric neurostimulation treatment within the
past 4 weeks, contraindications against one of the sub-
stances included in the treatment protocol (as listed in the
summary of product characteristics), and the inability to
sign written informed consent.
2.4. Participating physicians/acupuncturists
Participating trial physicians are from the above-mentioned
institutions. All are experienced in palliative symptom
296 S. Kramer et al.control. Pharmacological symptom control will be admin-
istered by a different physician than the physician who
performs the acupuncture. Acupuncturists will be medical
doctors who additionally fulfil the requirements for certi-
fication of the German medical Association.
2.5. Randomization and blinding
For each symptom separately, patients will be randomized,
using a series of sealed, sequentially numbered envelopes
containing the treatment assignments. The envelopes will
be prepared by an external person. When a patient fulfills
the inclusion criteria, the acupuncturist will open the
lowest numbered envelope to reveal the patient’s group
allocation. Neither the physician prescribing pharmacolog-
ical treatment according to the treatment protocols nor the
patient will know if they receive sham or verum treatment.
Patients will be told that they will receive acupuncture,
laser acupuncture, or standard medical treatment. They
will be further told that one treatment one of the two types
of acupuncture will be a placebo treatment. It will be left
open as to whether needle or laser acupuncture will be the
sham treatment.
2.6. Outcome measures
The main outcome parameter is the alteration of symptom
intensity prior to and at the end of the treatment sessions
after 2 weeks [visual analogue scale (VAS), 0e100-10/10].
Secondary outcome parameters are the administered
amounts of pharmacological symptom control (step on the
medical treatment protocol).
2.7. Statistical analysis
The aim of the statistical analysis is the comparison of the
main outcome measure [symptom intensity (VAS) after
2 weeks of treatment] between the three study groups
(intervention groups: verum needle acupuncture, control
groups: sham laser acupuncture control group and phar-
macological symptom control group). For this variable, a
non-normal distribution is assumed. Hence, a nonpara-
metric method, the KruskaleWallis test, will be applied.
Post hoc tests will be performed by pairwise comparisons of
the three study groups using ManneWhitney U test. Primary
outcome is defined as symptom VAS in the needle
acupuncture group in comparison to the pharmacological
symptom control group.
2.8. Consensus process on treatment protocols
2.8.1. Pharmacological treatment protocols
To date, there are no standard recommendations
regarding the most effective pharmacological combina-
tions for symptom control in palliative care. Therefore, we
chose the following procedure for the design of the
pharmacological treatment protocols for this trial. In a
first step, these protocols were designed according to
standard recommendations [25]. In a second step, the
protocols were reviewed by four experienced practitioners
of palliative care and by a pharmacologist experienced insupervising medical combinations in palliative care. In a
third step, the protocols were then sent out to German
experts with more than 10 years of experience in palliative
care. Medical treatment protocols are designed as a
multiple-step ladder.
2.8.2. Acupuncture treatment protocols
The treatment strategies for acupuncture were developed
based on a consensus process with experienced acupunc-
ture experts from the faculty of one of the major German
societies for medical acupuncture [German Medical
Acupuncture Association, or Deutsche A¨rztegesellschaft fu¨r
Akupunktur (DA¨GfA)]. A request was sent out to the mem-
bers of the faculty of the DA¨GfA asking them to list essen-
tial and optional acupuncture points in order of importance
for the treatment of each symptom. Eight of them sent
back their proposals, which were converted into the pro-
tocols according to the frequency in which the points were
named (Table 7).
2.9. Acupuncture treatment
Patients in the acupuncture group and the sham laser
group will receive Chinese-style acupuncture treatment
at the same acupuncture points. Detailed diagnosis ac-
cording to Traditional Chinese Medicine (TCM) diagnostic
considerations (including pulse and tongue diagnosis) is
assessed in every patient. Additional acupuncture points
chosen according to TCM diagnosis are recorded in both
groups.
Needle acupuncture will be performed using expendable
needles (Seirin 0.15  20 mm or 0.3  30 mm) at defined
acupuncture points. In patients with an extremely weak
constitution, thin needles were chosen. Needling may be
superficial, and deqi response (a deep aching or full feeling
at the needle) is not obligatory. Needle techniques can
include very point technique and dry needling.
Sham laser acupuncture was chosen as the placebo
treatment. The device is a nonfunctioning laser pen that
has been deactivated by the manufacturer (Handy CW 100,
Schwa-Medico, Ehringshausen, Germany). Only red light is
emitted. To strengthen the credibility of the imaginary
power of this sham procedure, visual and acoustic signals
accompany the red light emission. Patients will be treated
for 15 seconds per point without skin contact.
3. Results
For the planned study on symptom relief in palliative care,
seven different treatment protocols were designed in a
consensus process for both the acupuncture treatment
group and the control groups, as described below (Tables
1e6).
3.1. Acupuncture
Acupuncture treatment protocols were designed as semi-
standardized protocols with obligatory points that must be
treated. Additionally, the acupuncturist can choose from
the pool of optional points chosen according to the diag-
nostic pattern and its corresponding meridian systems. Both
Table 1 Medication protocol for dyspnea
Possible routes
of administration
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
po (not
extended-
release
preparations)/iv/sc
Opioid naive:
Morphine 1 mg/d
(1 mg po, o.d.)
Opioid naive:
Morphine
3 mg/d
(1 mg, po o.d.)
Opioid naive:
Morphine daily
dose < 15 mg/d
(1e3 mg
morphine o.d.)
Permanent daily
dose depending on
prior titration with
on-demand dose
(1e3 mg morphine o.d.)
See below See below See below
or or or
po (not
extended-release
preparations)/iv/sc
Nonopioid naive:
1  1/6 of
morphine equivalent
daily dose
Nonopioid naive:
3  1/6 of
morphine
equivalent
daily dose
Nonopioid naive:
>3  1/6 of
morphine
equivalent
daily dose
Increase of daily dose
depending on prior
titration with on-demand
dose (1 dose Z
1/6e1/10 of Tagesdosis)
See below See below See below
or or
Increase of
permanent
daily dose by >80%
and <200% of initial
morphine equivalent
dose
Increase of daily dose
by >200% of initial
morphine equivalent dose
Increase of
opioids does
not provide
sufficient
control of
dyspnea
Increase of
opioids does
not provide
sufficient
control of
dyspnea
Increase of
opioids does
not provide
sufficient
control of
dyspnea
iv/sc þ Midazolam
(Ramsay
score 2)
Anfangsdosis:
5e10 mg/24 h
þ Midazolam
(Ramsay score 2)
þ Midazolam s.u.
po/iv/sc þ Levomepromazine
40 mg/d
þ Levomepromazine
40 mg/d
iv/sc þ Midazolam
(Ramsay score >3)
Additional options Corticosteroids
(dexamethasone)
Inhalative oxygen Z þ 1 step each
Semistandardized protocol; pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom control can be achieved on one step, then treatment
will move in to the next step.
Corticosteroids (dexamethasone) or oxygen can be administered additionally (each þ1 step). The dose per step is for evaluation only; the individual dosing will follow the particular needs
of each patient.
iv Z intravenous; o.d. Z on-demand; po Z per os (oral); sc Z subcutaneous.
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Table 2 Medication protocol for depression
Possible
routes of
administration
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
po Mirtazapine 15 mg/d or
citalopram 20 mg/d
Mirtazapine 30 mg/d or
citalopram 40 mg/d
Mirtazapine
45 mg/d or
citalopram
60 mg/d
Mirtazapine
45 mg/d and
citalopram
20 mg/d
Mirtazapine
45 mg/d and
citalopram
40 mg/d
Mirtazapine
45 mg/d and
citalopram 40 mg/d
Mirtazapine 45 mg/d
and citalopram 40 mg/d
sl/po Lorazepam 6 mg/d lorazepam 6 mg/d
iv/sc þ Midazolam (Ramsay
score 2) Anfangsdosis:
5e10 mg/24 h
Pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom control can be achieved on one step, treatment will move on to the next step.
Caution is warranted in combining high doses of mirtazapine, citalopram and tramadol because of the risk of developing a serotonin syndrome.
The dose per step is for evaluation only; the individual dosing will follow the particular needs of each Patient.
iv Z intravenous; po Z per os (oral); sc Z subcutaneous; sl Z sublingual.
Table 3 Medication protocol for anxiety
Possible routes
of administration
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
sl/po Lorazepam
1.5 mg/d
Lorazepam
6 mg/d
Lorazepam
>6 mg/d
Lorazepam >6 mg/d Lorazepam >6 mg/d Lorazepam
>6 mg/d
Lorazepam >6 mg/d
sc/iv þ Midazolam (Ramsay
score 2) Anfangsdosis:
5e10 mg/24 h
þ Midazolam
(Ramsay score 2)
þ Midazolam
(Ramsay score 2)
þ Midazolam (higher
dosing as described
below)
po/sc/iv þ Haloperidol
1.5 mg/d (3  0.5 mg)
þ Haloperidol
9 mg/d (3  3 mg)
þ Haloperidol 9 mg/d
(3  3 mg)
iv/sc þ Midazolam (Ramsay
score >3)
Pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom control can be achieved on one step, treatment will move on to the next step.
The dose per step is for evaluation only; the individual dosing will follow the particular needs of each Patient.
iv Z intravenous; po Z per os (oral); sc Z subcutaneous; sl Z sublingual.
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Table 4 Medication protocol for pruritus
Possible routes
of administration
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6
po Skin care Desloratadine
5 mg/d
Dimetindene
maleate
12 mg/d
Dimetindene
maleate 4 mg/d, iv
Dimetindene
maleate 4 mg/d, iv
Dimetindene
maleate
4 mg/d, iv
iv/sc Dexamethasone
8 mg/d
Dexamethasone
8 mg/d
iv/sc þ Midazolam
(Ramsay
score 2)
Semistandardized protocol; pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom
control can be achieved on one step, treatment will move on to the next step; gabapentin, mirtazapine, methylnaltrexone can be
administered additionally (each þ1 step). The dose per step is for evaluation only; the individual dosing will follow the particular needs
of each Patient.
iv Z intravenous; po Z per os (oral); sc Z subcutaneous.
Table 5 Medication protocol for hypersalivation
Possible routes
of administration
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
po salvia Amitriptyline
25 mg/d
Amitriptyline
50 mg/d
Amitriptyline
75 mg/d
Amitriptyline
100 mg/d
Butylscopolamine
bromide 80 mg/d iv
Butylscopolamine
bromide
120e150 mg/d iv
Pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom control can be achieved in one
step, treatment will move on to the next step.
The dose per step is for evaluation only; the individual dosing will follow the particular needs of each Patient.
Table 6 Medication protocol for xerostomia
Possible routes
of administration
Step 1 Step 2 Step 3 Step 4 Step 5
Oral hygiene Oral hygiene Oral hygiene Oral hygiene Oral hygiene
Saliva substitutes Saliva substitutes Saliva substitutes Saliva substitutes
Air moistening Air moistening Air moistening
Pilocarpin 5 mg/d Pilocarpin 30 mg/d
Pharmacological symptom control according to the different steps on the ladder: if no sufficient symptom control can be achieved in one
step, treatment will move on to the next step.
The dose per step is for evaluation only; the individual dosing will follow the particular needs of each Patient.
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cording to the input from the experts. Depending on each
patient’s individual TCM diagnosis, further points were
possible as well as ear points or microsystem points. In very
weak patients, single-point acupuncture might be indi-
cated. For these cases, the most important acupuncture
point for each symptom are described. In this case, the
most important point is indicated by bold letters in Table 7
displaying the acupuncture scheme.
3.2. Pharmacological treatment
All experts agreed upon the statement that symptom con-
trol in palliative care requires multidisciplinary treatment
that focuses on psychological, social, and spiritual aspects.
These points are crucial. Thus, they will be provided to allpatients regardless of the treatment group in this study. We
have therefore not further mentioned these aspects in our
treatment protocols.
Treatment protocols were designed as treatment ladders
with multiple steps for each symptom. Sometimes the
different steps consist of different medications. Sometimes
they indicate the difference between a low and a high
dosage of the same substance. The pharmacological dos-
ages on the different steps are meant for evaluation. In-
dividual titration is allowed and required. For some
symptoms, additional treatments can be added at the best
time for the individual patient, resulting in an elevation on
the treatment ladder (þ1 step).
For some symptoms (dyspnea and anxiety), the last
treatment option is palliative sedation. In clinical practice
(including study participants), this step will only be taken in
Table 7 Semistandardized acupuncture treatment protocol for symptom control in palliative care
Symptom Obligatory acupoints Optional acupoints
Dyspnea CV17/PC 6/LU 7 LU1/LU5/LU9, Bl13, ST 40/LG26/Ex Ding-Chuan
Pruritus HT7/LI11; GV20 Le3/HT7; SP 10; LG14
Hypersalivation Lokal: ST4/GV 26/CV24/; ST 40; SP6/LI4/KD3; Bl20; LI20; ST36; further local: TW17/ST6/
Depression HT7; LI3/SP6/HT5 Bl 18/Bl/20/ST 36; Bl 15/Bl 44/Bl23/LG20/KD6/HT3/Bl52/CV6/
Gb25/CV17/Ying-tang/LU7
Anxiety HT7; KD 3; GV20 Bl23; Bl15; LU7/KD6/Bl44/Du¨3/Bl62/HT3
Xerostomia ST6; ST7; KD3 SP6; ST36/LI4/LI20/CV23/ST4
Obligatory points have to be treated (apart from the case of extreme weakness in which a single-point acupuncture can be chosen. In
this case, the most important point is indicated by bold letters). Depending on his/her opinion, the acupuncturist can choose from the
pool of optional points.
300 S. Kramer et al.very rare cases and only after a decision-forming process
that includes psychological/spiritual care and intensive
discussion by a multidisciplinary team. Patients who ex-
press the wish for palliative sedation will be excluded from
this study.
3.3. Dyspnea
Reasons for dyspnea can vary widely. This makes it diffi-
cult to settle for one treatment protocol. Symptomatic
relief will be mainly achieved owing to the depression of
breathing and the anxiolytic effect of opioids and benzo-
diazepines. In this context, opioids will be administered on
demand. The dosage will depend on the pre-existing
medication of the patient. If a patient is naı¨ve to opi-
oids, morphine will be given in an initial dose of 1 mg. In
patients on fast opioid medication, the demand dosage for
dyspnea will be 1/6 of the daily opioid dose. Besides the
treatment ladder, patients can receive additional corti-
costeroids and/or oxygen if reasonable. For evaluation,
this will be counted as one step higher on the treatment
ladder.
3.4. Anxiety/depression
For depression, mirtazapine or citalopram will be adminis-
tered in increasing dosages depending on whether a seda-
tive or activating effect is preferred. From step 5 onward,
both substances will be combined. For anxiety, lorazepam
will be given. If more than 6 mg/d is insufficient, a per-
manent midazolam infusion will be added starting with
5e10 mg/24 h. Apart from medication, psychological/spir-
itual care is also essential and will be provided to all pa-
tients in the study.
3.5. Pruritus
Skin care forms the basis for further treatment. An anti-
histamine is the first step of pharmacological treatment
followed by corticosteroids. Depending on the reason for
pruritus, patients can receive additional medications be-
side the treatment ladder (methylnaltrexone, gabapentin,
mirtazapine). For evaluation, each additional medication
will be counted as one step higher on the treatment ladder.3.6. Xerostomia
The treatment of xerostomia after radiotherapy includes
oral hygiene, saliva substitutes, and pilocarpine.
3.7. Hypersalivation
Medical treatment for hypersalivation is mainly restricted
to substances with anticholinergic activity as the antide-
pressant amitriptyline or butylscopolamine bromide. No
antihistamines, beta-blockers, or invasive strategies are
included owing to the limited scientific evidence of thera-
peutic effectiveness.
4. Discussion
We presented treatment schemes for both acupuncture and
pharmacological symptom relief of dyspnea, anxiety,
depression, pruritus, xerostomia, and hypersalivation
designed with the input of experienced practitioners in the
field of acupuncture or palliative care. The concept of
semistandardized treatment protocols was inspired by a
recent development in acupuncture trials: It has been
criticized that a fast acupuncture scheme in a study pro-
tocol can result in an inflexible and nonindividual treat-
ment. Assumedly, the results of these trials do not reflect
the effects of acupuncture in the general practice [26].
Thus, there is an ongoing discussion on how to develop
more individual acupuncture protocols that still meet re-
quirements for clinical trials. Some researchers choose a
semistandardized treatment protocol [27]. Others have
their treatment protocol developed in an expert consensus
process [28]. In the AcuPall protocol, we chose to combine
both ideas for optimum effects. Having treatment protocols
designed in a consensus process has the advantage that the
knowledge and experience of a number of experts are
combined. It is the strength of our study design that all
treatment protocols (medication and acupuncture) were
designed under the influence of expert opinions. However,
it is a shortcoming that none of the published methods
[29,30] were used for this consensus process.
During the process of designing pharmacological treat-
ment schemes, some experts expressed doubts that a
standardized protocol will sufficiently cover the patients’
needs. We still believe that it will be possible to provide a
Acupuncture for Symptom Relief in Palliative Care 301sufficient symptom control with the designed treatment
protocols. Meanwhile, in 2015 the German Palliative Care
Association has published S3 guidelines for some symptoms
in palliative care including dyspnea, cancer pain, obstipa-
tion, depression, communication, and the last phase of life
[31]. Recommended medication in these guidelines is in
accordance with our protocols. However, most recommen-
dations are expert opinions, as for some symptoms the
scientific evidence, even for frequently used drugs, is low,
mainly because of a lack of high-quality studies [32e36].
Even less evidence exists regarding the combination of
different substances. However, in a clinical scenario,
combinations of medication are often required for symptom
relief. Because of this lack of reference points, we believe
that our concept of creating a ladder scheme and adapting
it according to expert opinions was the best available pro-
cedure. The pilot phase of the planned study will provide
insight on this.
One point of critics might be the fact that the design of
this trial tries to meet too many requirements and is not
standardized enough. However, highly standardized effi-
cacy trials have been criticized for their limited impact on
decision making in clinical practice [37]. Thus, there is a
current trend in medicine for comparative effectiveness
research; the advantage of this type of research is its ca-
pacity to evaluate complementary and alternative treat-
ment methods such as acupuncture as an optional add-on to
conventional treatment, or as an alternative to it [38]. It
aims to investigate the overall treatment effects in more
pragmatic clinical settings and to examine the effective-
ness of a treatment in less standardized, but closer to real-
world scenarios [39]. Even though in this trial acupuncture
will be used as an add-on treatment, the option to compare
the steps on the treatment ladder of the different groups
will still provide insight on the direct therapeutic effec-
tiveness in symptom control.
Another item that has been discussed at length in
acupuncture research is the choice of the control proced-
ure [17e19]. The choice of sham-laser acupuncture in this
study has the disadvantage that technical devices are not
directly comparable to the manual skills of acupuncture.
However, it has the advantage over minimal acupuncture
(needle insertions at locations distant from real acupunc-
ture points) that activation of nonspecific physiological
effects such as stimulation of Ab fibers or C fibers can be
easily avoided. Furthermore, blinding of patients is easily
achieved. The treatment setting of laser acupuncture
carries equal weight to needle acupuncture in many re-
spects, for example, attention, relaxation, and concen-
tration on body sites distant from the affected painful area.
Sham-laser acupuncture has been shown to be a valid pla-
cebo control for acupuncture trials [23] and has been suc-
cessfully used in clinical studies before [40,41].
The design of this study (AcuPall) was planned to master
the challenge of combining two highly individualized dis-
ciplines of medicine (acupuncture and palliative care) with
the standardized processes in a high-quality clinical trial.
Semistandardized protocols for medical and acupuncture
treatment were developed with the help of experts in both
fields. Their clinical value will be demonstrated during the
course of the trial.Disclosure statement
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